Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 5 (2008), Issue 3 (March)

1. Is there an optimal comorbidity index for prostate cancer?
   Cancer, 112(5): 1043-50. [Abstract] [Full-text]
2. Prostate specific antigen kinetics in the management of prostate cancer.
   J Urol, 179(3): 821-6. [Abstract] [Full-text]
3. Change in prostate cancer grade over time in men followed expectantly for stage T1c disease.
   J Urol, 179(3): 901-4; discussion 904-5. [Abstract] [Full-text]
4. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy.
   J Urol, 179(3): 906-10; discussion 910. [Abstract] [Full-text]
5. Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors.
   J Urol, 179(3): 892-5; discussion 895. [Abstract] [Full-text]
6. 3-year actuarial biochemical recurrence-free survival following laparoscopic radical prostatectomy: experience from a tertiary referral center in the United States.
   J Urol, 179(3): 917-21; discussion 921-2. [Abstract] [Full-text]
7. Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer.
   J Urol, 179(3): 911-5; discussion 915-6. [Abstract] [Full-text]
8. Prostate cancer volume at biopsy predicts clinically significant upgrading.
   J Urol, 179(3): 896-900; discussion 900. [Abstract] [Full-text]
9. Complications of pelvic lymphadenectomy in 1,380 patients undergoing radical retropubic prostatectomy between 1993 and 2006.
   J Urol, 179(3): 923-8; discussion 928-9. [Abstract] [Full-text]
10. The impact of treatment choice for localized prostate cancer on response to phosphodiesterase inhibitors.
    J Urol, 179(3): 1072-6; discussion 1076. [Abstract] [Full-text]
11. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
    Cancer, 112(5): 1058-65. [Abstract] [Full-text]
12. The clinical management of patients with a small volume of prostatic cancer on biopsy: what are the risks of progression? A systematic review and meta-analysis.
    Cancer, 112(5): 971-81. [Abstract] [Full-text]
13. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
    J Clin Oncol, 26(7): 1148-59. [Abstract] [Full-text]
14. Evidence of a novel docetaxel sensitizer, garlic-derived S-allylmercaptocysteine, as a treatment option for hormone refractory prostate cancer.
    Int J Cancer, 122(9): 1941-8. [Abstract] [Full-text]
15. Rad9 has a functional role in human prostate carcinogenesis.
    Cancer Res, 68(5): 1267-74. [Abstract] [Full-text]
16. Total reconstruction of the vesico-urethral junction.
    BJU Int, 101(7): 871-7. [Abstract] [Full-text]
17. The effect of surgical volume, age and comorbidities on 30-day mortality after radical prostatectomy: a population-based analysis of 9208 consecutive cases.
    BJU Int, 101(7): 826-32. [Abstract] [Full-text]
18. Is the utility of prostate-specific antigen velocity for prostate cancer detection affected by age?
    BJU Int, 101(7): 817-21. [Abstract] [Full-text]
19. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality.
    BJU Int, 101(7): 809-16. [Abstract] [Full-text]
20. Pathological features of Gleason score 6 prostate cancers in the low and intermediate range of prostate-specific antigen level: is there a difference?
    BJU Int, 101(7): 822-5. [Abstract] [Full-text]
21. Factors affecting erectile function after radical retropubic prostatectomy: results from 1620 consecutive patients.
    BJU Int, 101(7): 833-6. [Abstract] [Full-text]
22. Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model.
    BJU Int, 101(7): 884-8. [Abstract] [Full-text]
23. Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy.
    BJU Int, 101(7): 841-5. [Abstract] [Full-text]
24. Comparison of cancers detected at only a sextant or alternative location.
    BJU Int, 101(7): 837-40. [Abstract] [Full-text]
25. Humoral response profiling reveals pathways to prostate cancer progression.
    Mol Cell Proteomics, 7(3): 600-11. [Abstract] [Full-text]
26. U19/Eaf2 knockout causes lung adenocarcinoma, B-cell lymphoma, hepatocellular carcinoma and prostatic intraepithelial neoplasia.
    Oncogene, 27(11): 1536-44. [Abstract] [Full-text]
27. Sarcomatoid carcinoma after radiation treatment of prostatic adenocarcinoma.
    Ann Diagn Pathol, 12(2): 142-5. [Abstract] [Full-text]
28. Interactions of cytokine gene polymorphisms in prostate cancer risk.
    Carcinogenesis, 29(3): 573-8. [Abstract] [Full-text]
29. Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies.
    Carcinogenesis, 29(3): 568-72. [Abstract] [Full-text]
30. External-beam radiotherapy for localized or locally advanced prostate cancer in Japan: a multi-institutional outcome analysis.
    Jpn J Clin Oncol, 38(3): 200-4. [Abstract] [Full-text]
31. Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer.
    Jpn J Clin Oncol, 38(3): 192-9. [Abstract] [Full-text]
32. Height, urban-born and prostate cancer risk in Japanese men.
    Jpn J Clin Oncol, 38(3): 205-13. [Abstract] [Full-text]
33. Dietary genistein inhibits metastasis of human prostate cancer in mice.
    Cancer Res, 68(6): 2024-32. [Abstract] [Full-text]
34. Genome-wide analysis of the homeobox C6 transcriptional network in prostate cancer.
    Cancer Res, 68(6): 1988-96. [Abstract] [Full-text]
35. Mammalian target of rapamycin repression by 3,3'-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells.
    Cancer Res, 68(6): 1927-34. [Abstract] [Full-text]
36. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling.
    Cancer Res, 68(6): 1843-50. [Abstract] [Full-text]
37. PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells.
    Cancer Res, 68(6): 1820-5. [Abstract] [Full-text]
38. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype.
    Cancer Res, 68(6): 1777-85. [Abstract] [Full-text]
39. CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism.
    Cancer Res, 68(6): 1715-22. [Abstract] [Full-text]
40. SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion.
    Cancer Res, 68(6): 1625-30. [Abstract] [Full-text]
41. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases.
    Am J Surg Pathol, 32(3): 461-7. [Abstract] [Full-text]
42. Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases.
    Am J Surg Pathol, 32(3): 468-72. [Abstract] [Full-text]
43. PCA3: a molecular urine assay for predicting prostate biopsy outcome.
    J Urol, 179(4): 1587-92. [Abstract] [Full-text]
44. Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy.
    J Urol, 179(4): 1593-7. [Abstract] [Full-text]
45. A contemporary study correlating prostate needle biopsy and radical prostatectomy Gleason score.
    J Urol, 179(4): 1335-8; discussion 1338-9. [Abstract] [Full-text]
46. Radical retropubic prostatectomy in immunosuppressed transplant recipients.
    J Urol, 179(4): 1349-52; discussion 1352-3. [Abstract] [Full-text]
47. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy.
    J Urol, 179(4): 1354-60; discussion 1360-1. [Abstract] [Full-text]
48. Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer.
    J Urol, 179(4): 1340-3. [Abstract] [Full-text]
49. Extended pattern prostate biopsy does not minimize the volume-grade bias in prostate cancer detection.
    J Urol, 179(4): 1332-4. [Abstract] [Full-text]
50. Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer.
    J Urol, 179(4): 1368-73; discussion 1373. [Abstract] [Full-text]
51. Systematic lateral prostate biopsy--are the benefits worth the costs?
    J Urol, 179(4): 1321-6. [Abstract] [Full-text]
52. Initial extended transrectal prostate biopsy--are more prostate cancers detected with 18 cores than with 12 cores?
    J Urol, 179(4): 1327-31; discussion 1331. [Abstract] [Full-text]
53. Pathological aggressiveness of prostatic carcinomas related to RNASEL R462Q allelic variants.
    J Urol, 179(4): 1344-8. [Abstract] [Full-text]
54. The influence of cardiovascular disease on health related quality of life in men with prostate cancer: a 4-year followup study.
    J Urol, 179(4): 1362-7; discussion 1367. [Abstract] [Full-text]
55. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
    J Urol, 179(4): 1235-42. [Abstract] [Full-text]
56. A dosimetric comparison between two intensity-modulated radiotherapy techniques: tomotherapy vs dynamic linear accelerator.
    Br J Radiol, 81(964): 333-40. [Abstract] [Full-text]
57. Re-defining rectal volume and DVH for analysis of rectal morbidity risk after radiotherapy for early prostate cancer.
    Br J Radiol, 81(964): 327-32. [Abstract] [Full-text]
58. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.
    J Clin Oncol, 26(9): 1532-6. [Abstract] [Full-text]
59. External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy.
    J Clin Oncol, 26(9): 1526-31. [Abstract] [Full-text]
60. Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate.
    Pharmacogenomics J, 8(2): 147-51. [Abstract] [Full-text]
61. SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer.
    Hum Mol Genet, 17(7): 1031-42. [Abstract] [Full-text]
62. Quality of life and satisfaction with outcome among prostate-cancer survivors.
    N Engl J Med, 358(12): 1250-61. [Abstract] [Full-text]
63. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
    Nat Rev Cancer, 8(4): 268-78. [Abstract] [Full-text]
64. Cancer control and the preservation of neurovascular tissue: how to meet competing goals during robotic radical prostatectomy.
    BJU Int, 101(8): 1013-8. [Abstract] [Full-text]
65. How quality influences the clinical outcome of external beam radiotherapy for localized prostate cancer.
    BJU Int, 101(8): 944-7. [Abstract] [Full-text]
66. Measurement of factors influencing the participation of patients with prostate cancer in clinical trials: a Canadian perspective.
    BJU Int, 101(8): 982-7. [Abstract] [Full-text]
67. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
    Int J Cancer, 122(10): 2368-76. [Abstract] [Full-text]
68. Antibodies against the cancer-testis antigen CTSP-1 are frequently found in prostate cancer patients and are an independent prognostic factor for biochemical-recurrence.
    Int J Cancer, 122(10): 2385-90. [Abstract] [Full-text]
69. Endogenous sex hormones and the risk of prostate cancer: a prospective study.
    Int J Cancer, 122(10): 2345-50. [Abstract] [Full-text]
70. Identification of E2F1 as a positive transcriptional regulator for delta-catenin.
    Biochem Biophys Res Commun, 369(2): 414-20. [Abstract] [Full-text]
71. Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells.
    Biochem Biophys Res Commun, 369(2): 292-6. [Abstract] [Full-text]
72. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.
    Ann Oncol, 19(4): 746-51. [Abstract] [Full-text]
73. Role of hormonal and other factors in human prostate cancer.
    J Toxicol Environ Health B Crit Rev, 11(3): 242-59. [Abstract] [Full-text]
74. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis.
    Oncogene, 27(14): 2055-63. [Abstract] [Full-text]
75. Complex patterns of ETS gene alteration arise during cancer development in the human prostate.
    Oncogene, 27(14): 1993-2003. [Abstract] [Full-text]
76. The effect of comorbidity and socioeconomic status on sexual and urinary function and on general health-related quality of life in men treated with radical prostatectomy for localized prostate cancer.
    J Sex Med, 5(4): 919-27. [Abstract] [Full-text]
77. Prostate cancer: role of pretreatment MR in predicting outcome after external-beam radiation therapy--initial experience.
    Radiology, 247(1): 141-6. [Abstract] [Full-text]
78. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.
    Lancet Oncol, 9(4): 342-51. [Abstract] [Full-text]
79. Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer.
    J Clin Pathol, 61(4): 448-54. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.